On April 20, JiuzhouPharma’s Japanese subsidiary—Jiuzhou Pharma Laboratory Co., Ltd.—officially inaugurated its new “Isolated Lab” at the Toray Kamakura site.

The launch of this advanced facility marks another step forward in JiuzhouPharma’s integrated “global resources + local services” model, enabling more efficient, secure, and reliable R&D and manufacturing support for clients across Japan and the Asia-Pacific region.

From Lab Scale to Kilogram Scale: A Fully Localized Closed-Loop in Japan

The new “Isolated Lab” removes the geographical barriers typically associated with cross-border collaboration by enabling end-to-end project execution entirely within Japan.

From early-stage micro-scale synthesis to kilogram-scale process development, all activities are conducted in a safe, controlled, and compliant local environment. This significantly improves project timelines while reducing risks related to logistics, communication, and regulatory complexity—helping accelerate innovative drug development.

Core Advantages: Strengthening CDMO Capabilities

1️⃣ Seamless Integration with Global Manufacturing Resources
As a strategic front-end in Japan, the lab is directly connected to JiuzhouPharma’s large-scale manufacturing system and advanced technology platforms:

• Leveraging global capacity and process expertise
• Introducing scalability considerations early in development
• Delivering one-stop solutions aligned with international standards

2️⃣ Integrated Capabilities from Lab to Kilogram Scale
Equipped with kilogram-scale capabilities, the lab enables:

• Smooth transition from gram-scale screening to kg-scale production
• No need for overseas sample transfer
• Faster iteration and validation within Japan

3️⃣ Flexible, High-Security Project Environment
Located in a dedicated, physically isolated space at the Toray Kamakura site, the facility offers:

• Segregated laboratory environments
• Flexible and customized project management
• Robust confidentiality and data protection systems

Ensuring strong IP protection while enabling efficient collaboration.

Enabling “Global Resources × Local Services”

The launch of the “Isolated Lab” represents a key extension of JiuzhouPharma’s global CDMO network in Japan, enabling:

• Stronger synergy between global manufacturing and local services
• Integration of scale-up capabilities with agile R&D
• Alignment of international standards with local customer needs

Looking ahead, JiuzhouPharma will continue to expand its global footprint and leverage advanced platforms like the “Isolated Lab” to accelerate the path from development to commercialization—bringing high-quality medicines to patients worldwide, faster.